PH II patient enrollment to small and that's why results are not very significant. PH III interim data this time
Phase II trials are small, as a rule. However, the amazing thing is that, despite the small sample sizes, a STATISTICALLY SIGNIFICANT improvement in DFS was observed. This is pretty exciting news for a phase II trial, especially as the phase III trial is targeting the same subpopulation in which the most dramatic phase II results were observed.
This doesn't guarantee success in phase III, but it shows a very high likelihood of success, at least from an efficacy standpoint.
Every expert in oncology that has been interviewed says this ground breaking work. They all say have patience. They all say this is the beginning of the end for cancer. The market responds to greed and avarice and just down right stupidity. If you can afford to hold for another 4 years you will see a reward well above the market returns. Just this year my stock is up well over 25%. This stock is not just a casual buy. Long term huge reward.